Radiolabeled 2-deoxy-2-(18F)fluoro-d-glucose (FDG) PET/CT imaging was performed 4, 8 and 12 weeks after Mtb challenge. Imaging was performed using a MultiScan LFER-150 PET/CT scanner (Mediso Medical Imaging Systems) housed within our biosafety level 3 facility as previously described66 (link),67 (link). Co-registered PET/CT images were analysed using OsiriX MD software (version 12.5.2, Pixmeo) to enumerate granulomas and to calculate the total FDG avidity of the lungs, exclusive of lymph nodes, which are a quantitative measure of total inflammation in the lungs66 (link),68 . For historical controls, PET/CT scans were performed using a microPET Focus 220 preclinical PET scanner (Siemens Molecular Solutions) and a clinical eight-slice helical CT scanner (NeuroLogica Corporation)68 . Thoracic lymphadenopathy and extrapulmonary dissemination of Mtb to the spleen and/or liver were also assessed qualitatively on these scans.
Free full text: Click here